OptiBiotix Health PLC Appointment of European Sales Leader - ProBiotix (5475V)
04 Diciembre 2019 - 1:00AM
UK Regulatory
TIDMOPTI
RNS Number : 5475V
OptiBiotix Health PLC
04 December 2019
OptiBiotix Health plc
("OptiBiotix" or the "Company")
Appointment of European Sales Leader for ProBiotix Health
Ltd
OptiBiotix Health plc (AIM: OPTI), a life sciences business
developing compounds to tackle obesity, high cholesterol, diabetes
and skin care, announces the appointment of Mikkel Hvid-Hansen as
European Sales Leader of its wholly-owned subsidiary, ProBiotix
Health Ltd ("ProBiotix").
ProBiotix was created to develop science based healthy bacteria
called probiotics to reduce cardiovascular risk. Independent
clinical studies have shown its LP(LDL) (R) probiotic can reduce
key cardiovascular risk markers such as total cholesterol, LDL
(bad) cholesterol, and blood pressure by up to 36.7%, 13.9% and
5.1% respectively. Since launching its CholBiome(R) products
containing LP(LDL) (R) in May 2017, ProBiotix has signed over 23
agreements and its products are now commercialised in 23 countries.
LP(LDL) (R) was designated Generally Recognized As Safe ("GRAS") by
an independent Expert GRAS Panel in the United States in February
2019, which extends its applications from use as a supplement to
use as a functional ingredient in a wide range of food, dairy, and
beverage products in the USA.
Mikkel is joining ProBiotix from a position as International
Sales Manager from Cell Biotech Int. ("Cell Biotech"), a Korean
probiotic company selling bulk ingredients and finished products
internationally. Prior to joining Cell Biotech, Mikkel spent six
years as International Sales Manager at Bifodan where he had
responsibility for the sales of several probiotic OTC drugs.
Previously, Mikkel also worked for Lallemand, the world's third
largest probiotic company (1998-2006) and Eraco (1995-1998). Mikkel
brings extensive experience of commercialising probiotics products
and technologies, a wide network of industry contacts, and a strong
track record of rapidly growing sales.
Mikkel will be based in Denmark to support existing sales in
Europe and extend the market opportunities for LP(LDL) (R) within
the European probiotic supplement, food, and dairy markets.
Steve Prescott, CEO of ProBiotix Health Ltd., commented:
"Mikkel's experience and track record of launching new products and
growing sales within Europe brings over 20 years of commercial and
probiotic industry expertise to OptiBiotix's wholly owned probiotic
subsidiary, ProBiotix Health Ltd. His network of contacts provides
access to key customers which we hope will continue to drive
revenue growth of LP(LDL) (R) in supplement, food and
pharmaceutical products around the world. We are delighted that
Mikkel has joined ProBiotix Health at such an exciting stage of its
development transforming the company from R&D to commercial
sales focused."
This announcement contains inside information for the purposes
of Article 7 of EU Regulation 596/2014.
For further information, please contact:
OptiBiotix Health plc www.optibiotix.com
Stephen O'Hara, Chief Executive Contact via Walbrook
below
Cairn Financial Advisers LLP (NOMAD) Tel: 020 7213 0880
Liam Murray / Jo Turner / Ludovico Lazzaretti
finnCap (Broker) Tel: 020 7220 0500
Geoff Nash/ Kate Bannatyne (Corporate Finance)
Camille Gochez (Corporate Broking)
Walbrook PR Ltd Tel: 020 7933 8780 or optibiotix@walbrookpr.com
Anna Dunphy Mob: 07876 741 001
About OptiBiotix - www.optibiotix.com
OptiBiotix Health plc (AIM: OPTI), which was formed in March
2012, brings science to the development of compounds which modify
the human microbiome - the collective genome of the microbes in the
body - in order to prevent and manage human disease and promote
wellness.
OptiBiotix has an extensive R&D programme working with
leading academics in the development of microbial strains,
compounds, and formulations which are used as active ingredients
and supplements. More than 25 international food and healthcare
supplement companies have signed agreements with OptiBiotix to
incorporate their human microbiome modulators into a wide range of
food products and drinks.
OptiBiotix is also developing its own range of consumer
supplements and health products. The Company's current areas of
focus include obesity, cardiovascular health, and diabetes.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
MSCEXLFBKLFBFBV
(END) Dow Jones Newswires
December 04, 2019 02:00 ET (07:00 GMT)
Optibiotix Health (LSE:OPTI)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Optibiotix Health (LSE:OPTI)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024